Formulation of proteins with liposomes to improve the
pharmacokinetics, stability and toxicity of the proteins and Gene
Therapy by liposome-encapsulated DNA.
Employees: 150
Professionals: 50
Turnover (KUS$): 22,000
Exports (KUS$): 10,000
Overview
OMRIX BIOPHARMACEUTICALS LTD. is a marketing-stage biotechnology
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
company which develops and markets the unique surgical sealant
known as QUIXIL in Israel, Europe, Asia and Latin America, and as
CROSSEAL in the United States.
OMRIX BIOPHARMACEUTICALS also develops and markets a suite of
immunology products. The Company's objective is to leverage its
expertise in plasma fractionation to develop, manufacture and
market specialized plasma-derived products.
OMRIX BIOPHARMACEUTICALS ranks as the third-largest
biotechnological company of its size in Israel. Headquartered in
Brussels, Belgium, it maintains a Research and Development Center
in the Scientific Park in Nes Ziona, and the state-of-the-art
fractionation plant in Tel Hashomer, both located in Israel.
OMRIX BIOPHARMACEUTICALS set itself a goal to lead and supply a
wide range of requirements in the field of plasma products, by
means of R&D and production of both effective and safe products.
The company specializes in the production and distribution of a
whole palette of plasma products at international standards and
in accordance with the strictest and most advanced production
processes, while giving special emphasis to their safety, using
advanced processes for viral inactivation and removal.
On the second half of 2006 OMRIX BIOPHARMACEUTICALS entered into
two new strategic product development programs in anti-adhesion
and spine utilizing its fibrin sealant technology.
